It is expected to recover and grow by 15% this year, mainly due to a rapidly ageing population and increasing incomes, analysts at SSI Securities Corporation said.
According to a report by the company, social distancing and strict control at hospitals last year meant people with minor ailments did not go for treatment due, resulting in lower sales of both prescription and non-prescription drugs.
The incidence of health checks was 10-15% down until the fourth quarter.
Then, in the final quarter, after the pandemic was controlled, people again began going to hospitals that the number visiting hospitals went up by 5% year-on-year.
Last year there was a short supply of active pharmaceutical ingredients (API) from China and India due to social distancing and lockdowns and higher demand for them globally, causing drug prices to rise.
India and China account for 55% of the global API supply and nearly 70% of Vietnam’s requirements.
The prices of most APIs increased by 5-8% and pharmaceutical companies’ gross profit margin decreased by 1-3 percentage points in 2020 since they could not increase prices to compensate for this.
Construction of new pharmaceutical plants fell behind schedule.
According to the Ministry of Health, domestic drug production grew at 13.8% per year in 2015 - 19 backed by Government policies and construction of new plants.
SSI Research said however the industry was recovering.
Last year was notable for mergers and acquisitions in the industry. According to SSI Research, the total value of M&A deals was VND1.68 trillion (US$73 million) and they involved a number of foreign investors.
German generic drugmaker Stada paid VND400 billion to increase its stake in Pymepharco JSC from 70% to 76%. Japan’s Aska Pharmaceutical paid VND350 billion to acquire a 25% stake in Ha Tay Pharmaceutical JS Company.